NCT07602790Not yet recruiting
Expand Management of Blood Pressure With Renal Denervation in Patients Undergoing Staged PCI for Advanced Coronary Artery diseasE
Source: ClinicalTrials.gov · Last updated 22 May 2026
Brief summary (registry, in English)
EMBRACE is a randomized, controlled, multicenter clinical study evaluating the effect of renal denervation on clinical adverse events in hypertensive patients undergoing staged percutaneous coronary intervention (PCI) for multivessel coronary artery disease.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 1000 (estimated)
- First submitted
- 4 May 2026
- Start date
- Nov 2026
- Primary completion date
- Nov 2030
- Lead sponsor
- Ceric Sàrl
- NCT number
- NCT07602790
What you commit to
- Study type: Interventional
- Planned participants: 1000
- From Nov 2026 to the primary completion date, Nov 2030
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subject has undergone prior renal denervation.
Other illness
- Known secondary cause (e.g., renal artery stenosis, primary aldosteronism, pheochromocytoma, Cushing's syndrome, or other identifiable etiologies).
- Known history of polycystic kidney disease, unilateral kidney, or undergone renal transplant
- Failure of index procedure
- Acute MI, severe renal failure, need for mechanical circulatory support, or legal incapacity between the index and staged procedures resulting in loss of eligibility.
Lab values
- Severe renal failure (eGFR \<30 ml/min/1.73 m²)
- Known LVEF \<30%
Other
- \- Contraindication for RDN outlined by IFU
- Acute MI at time of the staged PCI procedure (AMI at time of the index PCI is allowed)
- Subject has renal artery anatomy that is ineligible for RDN treatment per Symplicity Spyral™ IFU
- Mechanical circulatory support during PCI
- Subject is under judicial protection, tutorship or curatorship
Who the study is looking for
- Subject with multi-vessel disease
- Having successful index PCI and planned staged procedure within 1-6 weeks to complete revascularization
- Subjects ≥21 years of age
- Office systolic blood pressure at index procedure and/or staged procedure (systolic blood pressure \>140 mmHg) while taking 2 or more antihypertensive drugs
- Subject agrees to have all study procedures performed, and is competent and willing to provide written, informed consent to participate in this clinical study prior to staged procedure
Age in the registry: 21 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.